Shaji S Kumar

390PUBLICATIONS
772CO-AUTHORS
Haematological tumoursModelling and simulationApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersNgā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (390)

|Sep 12, 2026
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity.

|Aug 31, 2026
Primary Plasma Cell Leukemia.

|Aug 29, 2026
Subtype specific artificial intelligence modelling of cardiac amyloidosis using echocardiography and electrocardiography.

|Aug 25, 2026
Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma.

|Aug 25, 2026
Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Pageof 65

Frequent Collaborators

127 joint publications

Angela Dispenzieri

115 joint publications

Morie Gertz

106 joint publications

Vincent S Rajkumar

102 joint publications

Nelson R Leung